AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Feasibility and Acceptability of Endoscopic Mastectomy in Patients With Breast Cancer

RecruitingNAAges 20 Years - 75 YearsFemaleUniversity Hospital, Montpellier
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Nipple -Sparing Mastectomy (NSM), with immediate breast reconstruction (IBR) can be offered to patients requiring mastectomy when the lesion is more than 2cm from the nipple. Endoscopic mastectomy is a technical alternative for small-volume breasts (cup sizes A, B, C), offering a NSM with IBR, but also concealing the scar on the axillary line. It can be performed with traditional laparoscopic equipment, making this technique much more accessible and less costly than robotic mastectomy. It uses a single-port device that is significantly less costly than robotic equipment. Feasibility and safety studies remain limited to the Asian continent, and it would undoubtedly be beneficial to initiate research in Europe to add this new technical option to our surgical arsenal. This study project aims to explore the feasibility and safety of endoscopic nipple-sparing mastectomy for breast cancer ind

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Women between 20 and 75 years. * Patient with an indication for curative mastectomy, either unilateral or bilateral, with nipple preservation: * Extensive Carcinoma In Situ (CIS), more than 2 cm from the nipple * Multicentric Infiltrating Carcinoma (IC), more than 2 cm from the nipple * Large volume Infiltrating Carcinoma, more than 2 cm from the nipple * IC or CIS for which the patient refuses conservative treatment, more than 2 cm from the nipple * Breast volumes: cup sizes A, B, or C as defined by underwear size, and glandular ptosis not exceeding grade 2 according to Regnault's classification * Patient wishing to undergo immediate breast reconstruction. * WHO/OMS (World Health Organization/Organisation Mondiale de la Santรฉ) performance status \<3 Exclusion Criteria: * Cutaneous carcinoma * Inflammatory breast * History of oncological breast surgery on the same breast * Patient who has received radiation treatment on the same breast * Breast hypertrophy requiring a nipple-bearing flap * Smoking โ‰ฅ 10 cigarettes/day * BMI \> 35 * Protected patient or unable to give consent according to Article L1121-8 of the French Public Health Code (CSP). * Patient participating in another interventional clinical study. * ASA (physical status score of the American Society of Anesthesiologists) \>2. * Pregnant or breastfeeding women according to Article L1121-5 of the CSP. * Vulnerable persons (those receiving psychiatric care, those deprived of liberty, and those admitted to a health or social institution) according to Article L1121-6 of the CSP. * Absence of effective contraception for patients of childbearing age. * Absence of affiliation with a social security scheme. * Absence of collected free, informed, and written consent.
๐Ÿ’Š

What it tests

  • Nipple-Sparing Mastectomy, with immediate breast reconstruction
๐Ÿ“

Where

1 site
Uhmontpellier
Montpellier, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy